See Inefficient Markets In Action
Research - Over last weekend, Pharmathene (PIP) affected a special one-time cash dividend of $2.91 per share of common stock. This is money received from its long-running … Continue Reading
Premium: Read NowShort Ideas
Weekly Rundown: Don’t Miss these Profits the Next Time Around
Long Ideas - It’s been just under five weeks since the PropThink team laid out the investment thesis for Diadexus (DDXS). We said, “We calculate a probability weighted … Continue Reading
Read NowThe Weekly Rundown: Some Unexpected Events and Some Profitable Trades
Long Ideas - The story of the week at PropThink was BioCryst Pharmaceuticals (BCRX), a short that rapidly went in the wrong direction as a series of unpredictable … Continue Reading
Read NowBioCryst’s Lead Drug Candidate Will Face Challenges, After FDA’s Likely Peramivir Rejection
Most Popular - As we wrote in a note to PropThink Premium subscribers on Monday July 29 before the market open, an imbalance in the supply of stock … Continue Reading
Read NowTengion: A Value Trap of Epic Proportions
Most Popular - At the end of June, biotech giant Celgene (CELG) made a $15M investment in a small and obscure biotech for the right-of-first-negotiation to one of its lead … Continue Reading
Read NowHere Are Some of PropThink’s Top Healthcare Investments from The Last Week
Long Ideas - Curis (CRIS) has been around for quite some time with little to show for it but a significant long-term loss and some dud product candidates. … Continue Reading
Read NowThese Stories Topped the List at PropThink This Week
Most Popular - The FDA accepted Durect’s (DRRX) New Drug Application for Posidur on Thursday, causing shares to gap up and continue higher through the day. Analysts expect … Continue Reading
Read Now